Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022

SELL
$0.13 - $76.84 $3 - $1,921
-25 Reduced 0.76%
3,285 $234,000
Q2 2022

Aug 10, 2022

SELL
$72.62 - $79.98 $42,918 - $47,268
-591 Reduced 15.15%
3,310 $255,000
Q1 2022

May 10, 2022

SELL
$61.48 - $73.72 $12,296 - $14,744
-200 Reduced 4.88%
3,901 $285,000
Q1 2021

May 12, 2021

SELL
$59.34 - $66.74 $17,802 - $20,022
-300 Reduced 6.82%
4,101 $259,000
Q4 2020

Feb 08, 2021

SELL
$57.74 - $65.43 $2,887 - $3,271
-50 Reduced 1.12%
4,401 $273,000
Q3 2020

Nov 10, 2020

BUY
$57.43 - $63.64 $17,229 - $19,092
300 Added 7.23%
4,451 $268,000
Q1 2020

May 07, 2020

SELL
$46.4 - $67.43 $11,832 - $17,194
-255 Reduced 5.79%
4,151 $231,000
Q4 2019

Feb 06, 2020

BUY
$49.21 - $64.19 $216,819 - $282,821
4,406 New
4,406 $283,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $126B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Rock Point Advisors, LLC Portfolio

Follow Rock Point Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Point Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rock Point Advisors, LLC with notifications on news.